111 related articles for article (PubMed ID: 23744711)
21. Antitumor activity of lobaplatin alone or in combination with antitubulin agents in non-small-cell lung cancer.
Xie CY; Xu YP; Jin W; Lou LG
Anticancer Drugs; 2012 Aug; 23(7):698-705. PubMed ID: 22441567
[TBL] [Abstract][Full Text] [Related]
22. Evidence of a direct relationship between the increase in the in vitro passage number of human non-small-cell-lung cancer primocultures and their chemosensitivity.
Kruczynski A; Kiss R
Anticancer Res; 1993; 13(2):507-13. PubMed ID: 7685990
[TBL] [Abstract][Full Text] [Related]
23. Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation: Efficacy of alectinib against ALK G1269A mutated cells.
Yoshimura Y; Kurasawa M; Yorozu K; Puig O; Bordogna W; Harada N
Cancer Chemother Pharmacol; 2016 Mar; 77(3):623-8. PubMed ID: 26849637
[TBL] [Abstract][Full Text] [Related]
24. Discovery of hybrid Hsp90 inhibitors and their anti-neoplastic effects against gefitinib-resistant non-small cell lung cancer (NSCLC).
Jeong CH; Park HB; Jang WJ; Jung SH; Seo YH
Bioorg Med Chem Lett; 2014 Jan; 24(1):224-7. PubMed ID: 24345447
[TBL] [Abstract][Full Text] [Related]
25. Curcumin induces apoptosis and inhibits growth of orthotopic human non-small cell lung cancer xenografts.
Lev-Ari S; Starr A; Katzburg S; Berkovich L; Rimmon A; Ben-Yosef R; Vexler A; Ron I; Earon G
J Nutr Biochem; 2014 Aug; 25(8):843-50. PubMed ID: 24835302
[TBL] [Abstract][Full Text] [Related]
26. Emerging concepts in the pathology and molecular biology of advanced non-small cell lung cancer.
Kulesza P; Ramchandran K; Patel JD
Am J Clin Pathol; 2011 Aug; 136(2):228-38. PubMed ID: 21757595
[TBL] [Abstract][Full Text] [Related]
27. New development of inhibitors targeting the PI3K/AKT/mTOR pathway in personalized treatment of non-small-cell lung cancer.
Sun Z; Wang Z; Liu X; Wang D
Anticancer Drugs; 2015 Jan; 26(1):1-14. PubMed ID: 25304988
[TBL] [Abstract][Full Text] [Related]
28. Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma.
Carter CA; Chen C; Brink C; Vincent P; Maxuitenko YY; Gilbert KS; Waud WR; Zhang X
Cancer Chemother Pharmacol; 2007 Feb; 59(2):183-95. PubMed ID: 16724239
[TBL] [Abstract][Full Text] [Related]
29. Chemotherapy for advanced stage non-small cell lung cancer.
Fathi AT; Brahmer JR
Semin Thorac Cardiovasc Surg; 2008; 20(3):210-6. PubMed ID: 19038730
[TBL] [Abstract][Full Text] [Related]
30. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
[TBL] [Abstract][Full Text] [Related]
31. The subunits of glutamate cysteine ligase enhance cisplatin resistance in human non-small cell lung cancer xenografts in vivo.
Fujimori S; Abe Y; Nishi M; Hamamoto A; Inoue Y; Ohnishi Y; Nishime C; Matsumoto H; Yamazaki H; Kijima H; Ueyama Y; Inoue H; Nakamura M
Int J Oncol; 2004 Aug; 25(2):413-8. PubMed ID: 15254739
[TBL] [Abstract][Full Text] [Related]
32. Orthotopic models of esophageal carcinoma and their use in drug discovery.
Gros SJ
Curr Protoc Pharmacol; 2011 Sep; Chapter 14():Unit14.20. PubMed ID: 21898333
[TBL] [Abstract][Full Text] [Related]
33. Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies.
Shalinsky DR; Brekken J; Zou H; Bloom LA; McDermott CD; Zook S; Varki NM; Appelt K
Clin Cancer Res; 1999 Jul; 5(7):1905-17. PubMed ID: 10430098
[TBL] [Abstract][Full Text] [Related]
34. The modifier subunit of glutamate cysteine ligase relates to cisplatin resistance in human small cell lung cancer xenografts in vivo.
Nishi M; Abe Y; Fujimori S; Hamamoto A; Inoue Y; Miyazaki N; Oida Y; Ikoma N; Ohnishi Y; Yamazaki H; Ueyama Y; Nakamura M
Oncol Rep; 2005 Aug; 14(2):421-4. PubMed ID: 16012725
[TBL] [Abstract][Full Text] [Related]
35. Preclinical assessment of cisplatin-based therapy versus docetaxel-based therapy on a panel of human non-small-cell lung cancer xenografts.
Némati F; Bras-Gonçalves R; Fontaine JJ; de Pinieux G; De Cremoux P; Chapelier A; Daniel C; Laurent-Puig P; Livartowski A; Judde JG; Bordier V; Poupon MF; Decaudin D
Anticancer Drugs; 2009 Nov; 20(10):932-40. PubMed ID: 19741504
[TBL] [Abstract][Full Text] [Related]
36. Biomarker strategy in lung cancer.
Esencay M; Watson A; Mukherjee K; Hanicq D; Gubernick SI
Nat Rev Drug Discov; 2018 Jan; 17(1):13-14. PubMed ID: 28959953
[No Abstract] [Full Text] [Related]
37. Animal models for modeling pancreatic cancer and novel drug discovery.
Bisht S; Feldmann G
Expert Opin Drug Discov; 2019 Feb; 14(2):127-142. PubMed ID: 30657339
[TBL] [Abstract][Full Text] [Related]
38. Patient-Derived Bladder Cancer Xenografts.
Bernardo C; Santos LL
Methods Mol Biol; 2018; 1655():169-175. PubMed ID: 28889386
[TBL] [Abstract][Full Text] [Related]
39. A tumor deconstruction platform identifies definitive end points in the evaluation of drug responses.
Naik RR; Singh AK; Mali AM; Khirade MF; Bapat SA
Oncogene; 2016 Feb; 35(6):727-37. PubMed ID: 25915841
[TBL] [Abstract][Full Text] [Related]
40. Development and histopathological characterization of tumorgraft models of pancreatic ductal adenocarcinoma.
Garcia PL; Council LN; Christein JD; Arnoletti JP; Heslin MJ; Gamblin TL; Richardson JH; Bjornsti MA; Yoon KJ
PLoS One; 2013; 8(10):e78183. PubMed ID: 24194913
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
